FDA ANALGESIC SUBCMTE. DECLINES TO ENDORSE SPECIFIC CLINICAL PAIN MODELS
This article was originally published in The Tan Sheet
Executive Summary
FDA ANALGESIC SUBCMTE. DECLINES TO ENDORSE SPECIFIC CLINICAL PAIN MODELS as general assays for establishing efficacy of an OTC analgesic due to concerns that such an approach would impede the future development of better clinical models. Discussion by the FDA subcommittee at its Sept. 9 meeting focusing on appropriate "primary" and "secondary" pain models ended when several members and outside experts expressed reservations about recommending one or two specific pain models as the basis for an Rx-to-OTC switch application.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning